|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chlorpromazine oligomer is a potentially active substance that inhibits human D-amino acid oxidase, product of a susceptibility gene for schizophrenia.
|
18615285 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Initial reports suggested G72 as an activator of D-amino acid oxidase (DAO), supporting the glutamate dysfunction hypothesis of schizophrenia.
|
19077230 |
2008 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DAO gene may be a susceptibility locus for schizophrenia.
|
19223009 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several studies of the dystrobrevin-binding protein 1 gene (DTNBP1), neuregulin 1 (NRG1), D-amino-acid oxidase (DAO), DAO activator (DAOA, G72), and metabotropic glutamate receptor 3 (GRM3) genes have suggested an association between variants of these genes and schizophrenia.
|
19439994 |
2009 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While the initial association of DAOA with schizophrenia and its functional effects on DAAO activity have not been replicated, its identification has led to the development of several DAAO inhibitors, e.g., AS057278, CBIO and Compound 8, that are active in animal models of antipsychotic action.
|
19591808 |
2009 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dysbindin and d-amino-acid-oxidase gene polymorphisms associated with positive and negative symptoms in schizophrenia.
|
19729970 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review also highlights issues that have a broader relevance beyond DAO itself: how should we weigh up convergent and cumulatively impressive, but individually inconclusive, pieces of evidence regarding the role that a given gene may have in the aetiology, pathophysiology and pharmacotherapy of schizophrenia?
|
19786963 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data support the hypothesis that DAO plays a role in schizophrenia, possibly in a gender-dependent manner.
|
20483168 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested the hypothesis that a variation in DAAO genotype would be associated with altered prefrontal function and altered functional connectivity in schizophrenia and bipolar disorder.
|
21421061 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest an influence of the gene in the neural substrate mediating sensorimotor gating and working memory, especially when combined with high anxiety and further validate DAO as a candidate gene for schizophrenia and spectrum disorders.
|
21471957 |
2011 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One such susceptibility gene encoding D-amino acid oxidase (DAO), an enzyme that metabolizes the NMDA receptor (NMDAR) co-agonist D-serine, has the potential to modulate NMDAR function in the context of schizophrenia.
|
21700703 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results raise doubt on the use of the rat as a model system for testing new drugs against schizophrenia and indicate a different physiological function of DAAO in rodents and humans.
|
21981077 |
2011 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was therefore to examine the impact of G72 rs746187 and DAAO rs2111902 genotypes on brain function in schizophrenia, bipolar disorder and healthy volunteers.
|
22239582 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
There have also been several lines of evidence correlating DAO with schizophrenia.
|
22892863 |
2012 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Characterization of human DAAO variants potentially related to an increased risk of schizophrenia.
|
23219954 |
2013 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Between-gene interactions including DAO*DISC1 , DAO*NRG1 and DAO*RASD2 and a within-gene interaction for CACNG2 were found among schizophrenia subjects with severe sustained attention deficits, suggesting a modifying effect of impaired neuropsychological functioning.
|
23555897 |
2013 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This region has been of significant interest to psychiatric genetics as it contains the Darier's disease locus and other proposed susceptibility genes (e.g., DAO, NOS1), and it has been linked to affective disorders and schizophrenia in multiple populations.
|
26440917 |
2015 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Haplotypes of the D-Amino Acid Oxidase Gene Are Significantly Associated with Schizophrenia and Its Neurocognitive Deficits.
|
26986737 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The product of the G72 gene is an activator of d-amino acid oxidase and has been suggested to play a role in the pathogenesis of schizophrenia.
|
27412497 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results provide additional evidence and indicate that the DAOA gene and DAOA-DAO gene-gene interactions might play a role for schizophrenia in a Taiwanese sample.
|
28285246 |
2017 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were significantly lower mean serum levels of d-Ser and SR and significantly higher mean serum levels of DAAO (<i>P</i>-value <0.01 for each) among schizophrenia patients when compared with the control group.
|
28435276 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data and methods may be useful in understanding the effects of sodium benzoate that have been seen in clinical trials of schizophrenia and Alzheimer's disease and to support the potential clinical assessment of other DAO inhibitors, such as PGM030756, which demonstrate good enzyme occupancy and D-serine increases following administration of low oral doses.
|
28780732 |
2017 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our systematic meta-analysis is the most updated one for the association of DAO, DAOA, and NRG1 SNPs with schizophrenia.
|
28864885 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The glutamate hypothesis of schizophrenia has proposed that increased DAO activity leads to decreased D-serine, which subsequently may lead to N-methyl-D-aspartate (NMDA) receptor hypofunction.
|
29114206 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we aimed to evaluate whether glutamatergic variants such as d-amino acid oxidase (<i>DAO</i>), DAO activator (<i>DAOA</i>)/<i>G72</i>, and neuregulin 1 (<i>NRG1</i>) single-nucleotide polymorphisms (SNPs) and their mRNA levels predicted (i) transition to schizophrenia spectrum disorders and (ii) research domain criteria (RDoC) domains, mainly negative valence and cognitive systems.
|
29326614 |
2017 |